EFFICACY AND SAFETY OF HIGH-DOSE CONSOLIDATION WITH AUTOLOGOUS BLOOD STEM CELL SUPPORT IN PATIENTS WITH HODGKIN`S LYMPHOMA: 10 YEARS OF EXPERIENCE IN ONE HOSPITAL
- 1Moscow Clinical Science and Research Center 52, Russia
Abstract
Relevance: Despite the introduction of highly effective treatment methods such as brentuximab vedotin and checkpoint inhibitors (nivolumab, pembrolizumab), stem cell transplantation remains relevant for patients with relapse/refractory Hodgkin's lymphoma. For such patients the probability of recovery after autoSCT is up to 60%, this indicator can be increased by using brentuximab vedotin or checkpoint inhibitors as consolidating or maintenance therapy. Materials and methods: From 2015 to 2025, 90 patients with Hodgkin's lymphoma underwent autoSCT in at the Moscow Clinical Science and Research Center 52: 46 (51%) men, 44 (49%) women, the median age was 32 years (19-58 years). According to the Ann Arbor staging, 3 patients (3%) had stage I, 34 (38%) - II, 22 (24%) - III, 31 (34%) - IV. The median number of therapy lines before autoSCT is 3 (2-8). The majority of patients had a complete metabolic response before autoSCT - 56 patients (83%), 7 (12%) achieved a partial report, 2 (5%) - stabilization. The pretransplant conditioning regimens were BEAM - 13 pts (15%), BeEAM - 75 pts (83%), CEAM – 2 pts (2%). The median number of transfused PBSCs is 6.25*10^6 CD34+cells (1.4 – 25.5). After autoSCT 34 patients (38%) received maintenance therapy with brentuximab vedotin (29 patients – 32%), nivolumab or pembrolizumab (4 patients – 4.4%) or a combination of BV+nivo (2 pts – 2%). Results: The median follow–up was 35 months (0-109). The median of leukocyte engraftment was 13 (8-31) days (18 for BEAM and 12 days for BeEAM). Infectious complications were represented by mucositis 3-4 grade (31% for BEAM vs 35% for BeEAM), bacteremia (15% for BEAM vs 23% for BeEAM), pneumonia (15% for BEAM vs 12% for BeEAM), clostridial colitis (23% for BEAM vs 16% for BeEAM), invasive aspergillosis (undetected on BEAM and 9% for BeEAM), invasive candidiasis (8% for BEAM vs 3% for BeEAM), reactivation of herpesvirus infections (31% for BEAM vs 28% for BeEAM). Transplant- related mortality was 4.4% (4 patients), the causes of mortality were infectious complications (3 patients - sepsis, 1 patient was CMV infection and secondary hemophagocytic syndrome). The 3-year overall survival (OS) was 88%, and the progressive–free survival (PFS) 80%. There were no significant differences in OS and PFS depending on the Ann-Arbor stage, the number of previous lines of therapy, the response to autoSCT, and the conditioning regimen, but the effect of maintenance therapy on OS and PFS was revealed: 3-year OS and PFS in the group of patients receiving maintenance therapy were 95% and 90%, in the group without maintenance therapy 84% (p=0.053) and 74% (p=0.058) accordingly. The use of checkpoint inhibitors showed advantages in OS and PFS in comparison with brentuximab-vedotin (OS 100% vs. 94%, PFS 100% vs. 87%), but the differences are not significant. Conclusion and conclusions: Despite highly effective first line treatment programs for the Hodgkin's lymphoma, autoSCT remains an effective method of consolidation for patients with R/R disease. Сonsidering the toxicity of conditioning regimes and the significant cure of this category of patients, effective methods of infection prevention in the early post-transplant period are necessary. Maintenance therapy with checkpoint inhibitors and/or brentuximab vedotin after autoSCT can significantly reduce the risk of relaps.
Related
- Real‐World Treatment Patterns, Burden of Illness, and Survival of Autologous Stem Cell Transplant‐Ineligible Patients With Mantle Cell Lymphoma in Ontario, Canada
- Nutritional Risk, Weight Loss, and Inflammatory Profiles During Autologous Stem Cell Transplantation: Clinical Correlates in Patients with Lymphoma and Multiple Myeloma
- Safety, Efficacy, and Pharmacokinetics of Unecritinib (TQ-B3101) in Pediatric Patients With Relapsed/Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large-Cell Lymphoma: A Phase I Study.
- Efficacy of autologous adipose-derived stromal vascular fraction and platelet-rich plasma intracavernous injections in patients with erectile dysfunction: a retrospective comparative study
- On closing the gap: anti-PD-1-based salvage in relapsed/ refractory classical Hodgkin lymphoma. Comment on: “Mind the gap: anti-PD-1 salvage before autologous transplantation in classical Hodgkin lymphoma”
BibTeX
@article{karimova2026efficacy,
title = {{EFFICACY AND SAFETY OF HIGH-DOSE CONSOLIDATION WITH AUTOLOGOUS BLOOD STEM CELL SUPPORT IN PATIENTS WITH HODGKIN`S LYMPHOMA: 10 YEARS OF EXPERIENCE IN ONE HOSPITAL}},
author = {Ekaterina KARIMOVA and Eugenia ZHELNOVA and Leonid KHORDZHASOV and Ekaterina GRISHINA and Maryana LYSENKO},
journal = {Hematology, Transfusion and Cell Therapy},
year = {2026},
month = oct,
doi = {10.1016/j.htct.2026.107705},
url = {https://doi.org/10.1016/j.htct.2026.107705},
note = {CC BY},
}
RIS
TY - JOUR
TI - EFFICACY AND SAFETY OF HIGH-DOSE CONSOLIDATION WITH AUTOLOGOUS BLOOD STEM CELL SUPPORT IN PATIENTS WITH HODGKIN`S LYMPHOMA: 10 YEARS OF EXPERIENCE IN ONE HOSPITAL
AU - Ekaterina KARIMOVA
AU - Eugenia ZHELNOVA
AU - Leonid KHORDZHASOV
AU - Ekaterina GRISHINA
AU - Maryana LYSENKO
PY - 2026
DA - 2026/10/23
JO - Hematology, Transfusion and Cell Therapy
DO - 10.1016/j.htct.2026.107705
UR - https://doi.org/10.1016/j.htct.2026.107705
AB - Relevance: Despite the introduction of highly effective treatment methods such as brentuximab vedotin and checkpoint inhibitors (nivolumab, pembrolizumab), stem cell transplantation remains relevant for patients with relapse/refractory Hodgkin's lymphoma. For such patients the probability of recovery after autoSCT is up to 60%, this indicator can be increased by using brentuximab vedotin or checkpoint inhibitors as consolidating or maintenance therapy. Materials and methods: From 2015 to 2025, 90 patients with Hodgkin's lymphoma underwent autoSCT in at the Moscow Clinical Science and Research Center 52: 46 (51%) men, 44 (49%) women, the median age was 32 years (19-58 years). According to the Ann Arbor staging, 3 patients (3%) had stage I, 34 (38%) - II, 22 (24%) - III, 31 (34%) - IV. The median number of therapy lines before autoSCT is 3 (2-8). The majority of patients had a complete metabolic response before autoSCT - 56 patients (83%), 7 (12%) achieved a partial report, 2 (5%) - stabilization. The pretransplant conditioning regimens were BEAM - 13 pts (15%), BeEAM - 75 pts (83%), CEAM – 2 pts (2%). The median number of transfused PBSCs is 6.25*10^6 CD34+cells (1.4 – 25.5). After autoSCT 34 patients (38%) received maintenance therapy with brentuximab vedotin (29 patients – 32%), nivolumab or pembrolizumab (4 patients – 4.4%) or a combination of BV+nivo (2 pts – 2%). Results: The median follow–up was 35 months (0-109). The median of leukocyte engraftment was 13 (8-31) days (18 for BEAM and 12 days for BeEAM). Infectious complications were represented by mucositis 3-4 grade (31% for BEAM vs 35% for BeEAM), bacteremia (15% for BEAM vs 23% for BeEAM), pneumonia (15% for BEAM vs 12% for BeEAM), clostridial colitis (23% for BEAM vs 16% for BeEAM), invasive aspergillosis (undetected on BEAM and 9% for BeEAM), invasive candidiasis (8% for BEAM vs 3% for BeEAM), reactivation of herpesvirus infections (31% for BEAM vs 28% for BeEAM). Transplant- related mortality was 4.4% (4 patients), the causes of mortality were infectious complications (3 patients - sepsis, 1 patient was CMV infection and secondary hemophagocytic syndrome). The 3-year overall survival (OS) was 88%, and the progressive–free survival (PFS) 80%. There were no significant differences in OS and PFS depending on the Ann-Arbor stage, the number of previous lines of therapy, the response to autoSCT, and the conditioning regimen, but the effect of maintenance therapy on OS and PFS was revealed: 3-year OS and PFS in the group of patients receiving maintenance therapy were 95% and 90%, in the group without maintenance therapy 84% (p=0.053) and 74% (p=0.058) accordingly. The use of checkpoint inhibitors showed advantages in OS and PFS in comparison with brentuximab-vedotin (OS 100% vs. 94%, PFS 100% vs. 87%), but the differences are not significant. Conclusion and conclusions: Despite highly effective first line treatment programs for the Hodgkin's lymphoma, autoSCT remains an effective method of consolidation for patients with R/R disease. Сonsidering the toxicity of conditioning regimes and the significant cure of this category of patients, effective methods of infection prevention in the early post-transplant period are necessary. Maintenance therapy with checkpoint inhibitors and/or brentuximab vedotin after autoSCT can significantly reduce the risk of relaps.
SN - 2531-1379
SN - 2531-1387
ER -